Welcome to Scribd. Sign in or start your free trial to enjoy unlimited e-books, audiobooks & documents.Find out more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Aarkstore.com - VEGF Inhibition- Therapy-Indicating and Prognostic Biomarkers, 2011

Aarkstore.com - VEGF Inhibition- Therapy-Indicating and Prognostic Biomarkers, 2011

Ratings:
(0)
|Views: 1|Likes:
Published by namrata17588
Aarkstore.com announce a new report "VEGF Inhibition- Therapy-Indicating and Prognostic Biomarkers, 2011" through its vast collection of market research report.
Aarkstore.com announce a new report "VEGF Inhibition- Therapy-Indicating and Prognostic Biomarkers, 2011" through its vast collection of market research report.

More info:

Categories:Types, Business/Law
Published by: namrata17588 on Feb 18, 2013
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOCX, PDF, TXT or read online from Scribd
See more
See less

05/14/2014

pdf

text

original

 
 
Aarkstore.com announces, a new market research report is available in its vast collection:
Summary
 Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has beenextensively studied and over-expression is seen in many cancers. Today, VEGF is targeted usingantibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for manycancers, including colorectal and non-small cell lung cancer.While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, thesebenefits are not seen in all patients and cancer types. Today, there is an urgent need for predictivebiomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. Thisreport (see brochure) provides a review of findings to date on biomarkers associated with the usebevacizumab (Avastin®); both therapy-indicating and prognostic.The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy isin its early stages, however important advances have been made. This report identifies the latestfindings on ten different cancers and includes an evaluation of candidate biomarkers as a basis forinterpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.
Key content:
 
• A comprehensive review of clinical studies that have identified bi
omarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis
• Biomarkers identified or further evaluated in the last three years, up until October 2011. From a
background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the mostimportant findings have been identified for their significance and value to patients and in designingclinical trials
• Covering more than ten cancers including colorectal, ovarian, renal, breast, pa
ncreatic, prostate,lung and liver cancers
• Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria
 
• Studies indicate drug type associations together with comparative therapies
 
• Descriptions and explanation of 
all biomarkers identified (proteins, genotypes, imaging etc)
• Biomarker associations are categorised according to three broad criteria, namely “positive
-therapy-
indicating” (response, improved response, improved outcome or prognosis), “non
-therapy-indica
ting” (no differences in tumour response, outcome or prognosis) and “negative
-therapy-
indicating” (adverse
events, poor outcome or prognosis)
Table of Contents:
 
Executive Summary
 Chapter 1: Background (p.18)1.1 VEGF Inhibition
 
 
1.2 Bevacizumab1.3 Biomarkers1.4 This ReportChapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p. 22)Summary2.1 Introduction2.2 Glycoprotein2.3 Protein2.4 Protein2.5 Cells2.6 Genetic2.7 Physical2.8 Genetic2.9 Protein2.10 Proteins2.11 Proteins and Genetic2.12 Image2.13 Proteins2.14 ProteinChapter 3 Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.42)Summary3.1 Introduction3.2 Protein3.3 Protein3.4 Protein3.5 Protein3.6 Protein3.7 Genetic3.8 Protein
More Related Reports :

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->